Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.

摘要: Recent research in the pharmacotherapy of Parkinson's disease (PD) has been able to provide numerous agents for symptomatic control motor impairments, but failed identify substances capable slow down or even halt progression disease. In absence disease-modifying therapies, affected patients develop marked disability within some years after onset symptoms, which can be alleviated eventually not prevented with currently available medical and surgical therapies. Despite promising results from preclinical studies, outcomes clinical neuroprotection trials have repeatedly disappointing, calls a review our approach this topic. This article attempts explain need neuroprotective therapies PD, discusses limitations previous provides food thought future PD. Previous experiences studies may discouraging, also teach us important lessons next generation trials. Firstly, used animal models PD refined order more reliably predict efficacy putative subsequent studies. Furthermore, changes methodology design are required exclude an impact confounding effects on observations. Finally, coordination concentration most will necessary accelerate search Just as pathogenesis is manifold, it multilateral that leads breakthrough finding if they exist.